Defining AI-Driven NHI Safety Nets and Precision Health Journeys

At the intersection of global medical cost pressures and Taiwan’s National Health Insurance (NHI) reforms in 2025, PatientsForce positions itself as a “Strategic Market Access Bridge” within the healthcare ecosystem. We not only address the financial affordability of innovative drugs but also implement large-scale patient medication support through AI technology.

2025 Three Core Value Indicators:

• NT$10 Billion Milestone: Successfully facilitated Patient Support Programs (PSP) with a cumulative drug subsidy value exceeding NT$10 billion, with 2025 single-year subsidies reaching NT$2.3 billion.
• Global ESG Leadership: Awarded the 2025 EcoVadis Sustainability Bronze Medal, ranking in the top 23% of the industry globally, with “Sustainable Procurement” soaring into the top 4%.
• High-Efficiency Operations: Developed and applied “Agentic AI” and automated customer service to boost administrative efficiency, achieving a target saving of over 200 man-days per year while maintaining a lean expert team.

Collaboration Between NHI Review Gaps and New Drug Funds

Despite the government establishing the NT$10 billion “Cancer Drug Fund (CDF)” in 2025, a significant gap remains for patients during the “review waiting period” between drug approval and official NHI reimbursement.

PatientsForce’s Role:

• NHI Safety Net: Acting as a “third player” in public-private partnerships to bridge the supply-demand time gap in the self-pay market, alleviating Financial Toxicity for nearly 10,000 cancer patients in 2025.
• NHI and CDF Connector: With limited budgets, we ensured early market access for innovative drugs, helping nearly 15,000 enrolled patients receive timely treatment through PSP projects.

 

2025 Operational Data: Service Regions and Clinical Distribution

PatientsForce is a qualified PSP supplier for over 80% of the Top 15 multinational pharmaceutical companies and a partner to listed Taiwanese biotech firms.

📊 Key Metrics

Metric	2025 Cumulative Results	Strategic Value
New Patients Served Annually	>15,000	Establishes a robust real-world evidence (RWE) foundation to support sustainable scale-up
Total Cumulative Patients Served	>60,000	The largest Patient Support Program (PSP) management platform in Taiwan
Annual Prescription Fulfillment Volume	>45,000 prescriptions	High-frequency, high-precision pharmaceutical logistics coordination and compliance management
Partner Hospitals	>750 institutions	100% coverage of Taiwan’s healthcare network, including all medical centers
Partner Physicians	>3,600 physicians	Comprehensive engagement with key opinion leaders (KOLs) across major specialties
Managed Therapy Products	>90 products	Coverage of over 80% of high-value innovative and specialty pharmaceuticals

🔍 Regional and Therapeutic Analysis:

PatientsForce is a qualified PSP supplier for over 80% of the Top 15 multinational pharmaceutical companies and a partner to listed Taiwanese biotech firms.

• Oncology (70%): Focuses on targeted and immunotherapy, effectively reducing treatment discontinuation rates for advanced cancer patients.
• Chronic and Rare Diseases (30%): Includes rare disease assistance, biologics, osteoporosis, and pediatric care to improve patient adherence.
• Regional Centers (North/Central/South): Highly concentrated in major medical centers as core nodes for subsidy disbursement.
• Remote Areas: Reached nearly 200 partner pharmacies and GP clinics via digital platforms in 2025, extending PSP services to communities and homes.
• Cross-Hospital Coverage: Possesses cross-system data integration capabilities to provide standardized project execution for pharma companies.

Professional Medical Management: “Value-Added Care” in the Medication Journey

PatientsForce has upgraded its traditional subsidy platform into the “Generation 2.0 PSP Patient Support Welfare System,” providing value-added professional services throughout the patient journey.

🛡️ Details of Value-Based Healthcare Services:

• Precision Diagnosis Companion Service: Clinical nursing teams assist patients in identifying suitable genotypes (aligned with NGS reimbursement trends) to shorten the time from diagnosis to starting targeted therapy.
• Full-Journey Management: Covers 8 core steps, including educational care, transportation booking, and home follow-ups, significantly improving Adherence.
• Adverse Event (AE) Reporting: Real-time monitoring helps pharma companies collect high-quality Real-World Evidence (RWE) to support future NHI reimbursement data.

 

AI Revolution: Defining New Standards for High-Efficiency Administration

In 2025, AI is the technological foundation for scaled services.

• OCR + NLP Intelligent Document Processing: Processing over 600,000 internal documents annually. Powered by AI models, the solution accelerates processing to near real-time (seconds-level) turnaround, ensures data security, and significantly reduces error rates.
• Scalable Operational Benefits: The digital management platform saves approximately 200 days of administrative labor annually, enabling the company to handle more than 80 complex projects simultaneously while achieving exceptionally high employee efficiency.

 

ESG Leadership: 2025 EcoVadis Global Sustainability Achievement

The EcoVadis Bronze Medal awarded to the PatientsForce Group (CareSymmetry) in 2025 is a key indicator of “Supply Chain Resilience”.

🎖️ Percentile Rank Analysis:

• Overall: Top 23% globally.
• Business Ethics: Top 20%, demonstrating excellence in data privacy (ISO 27001/27701) and transparent management.
• Labor & Human Rights: Ranked in the top 27%, reflecting our commitment to fostering a diverse, equitable, and inclusive (DEI) workplace environment.
• Sustainable Procurement: Ranked in the top 4%—a pinnacle industry level that demonstrates leadership in integrating pharmaceutical supply chains and driving paperless, green logistics.

 

2026 Outlook: Expanding Patient Support and Empowerment Across Asia-Pacific

 

Looking ahead to 2026, PatientsForce will continue to focus on expanding the capacity and value of patient support services through two strategic pillars:

• Expanding Support to “Named Patient” Programs: We aim to establish an international network for “Named Patient” medications. This will assist patients in Taiwan who have urgent medical needs for drugs that are not yet licensed or covered by NHI, ensuring they receive prescribed treatments in a timely manner. By leveraging digital management and direct interfaces with global pharmaceutical manufacturers, we will streamline the special import process.
• Technology-Driven Home Care (Escort & Home Care): We will integrate AIoT-enabled remote smart care with nursing manpower for “Hospital-at-Home” (HaH) initiatives. By utilizing real-time physiological data alerts and accessible community nursing resources, we ensure high-quality care beyond the hospital walls.

Our Vision: By combining the scalability of technology with the human touch of healthcare professionals, we strive to reduce the burden borne by patients for every new therapy, while expanding the reach of precision care.

This is not merely a transformation in healthcare accessibility—it is a long-term commitment to every life we serve.